GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Jiangsu Lianhuan Pharmaceutical Co Ltd (SHSE:600513) » Definitions » Cash And Cash Equivalents

Jiangsu Lianhuan Pharmaceutical Co (SHSE:600513) Cash And Cash Equivalents : ¥237 Mil (As of Mar. 2024)


View and export this data going back to 2003. Start your Free Trial

What is Jiangsu Lianhuan Pharmaceutical Co Cash And Cash Equivalents?

Jiangsu Lianhuan Pharmaceutical Co's quarterly cash and cash equivalents increased from Sep. 2023 (¥204.43 Mil) to Dec. 2023 (¥281.38 Mil) but then stayed the same from Dec. 2023 (¥281.38 Mil) to Mar. 2024 (¥237.13 Mil).

Jiangsu Lianhuan Pharmaceutical Co's annual cash and cash equivalents declined from Dec. 2021 (¥330.69 Mil) to Dec. 2022 (¥330.65 Mil) and declined from Dec. 2022 (¥330.65 Mil) to Dec. 2023 (¥281.38 Mil).


Jiangsu Lianhuan Pharmaceutical Co Cash And Cash Equivalents Historical Data

The historical data trend for Jiangsu Lianhuan Pharmaceutical Co's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jiangsu Lianhuan Pharmaceutical Co Cash And Cash Equivalents Chart

Jiangsu Lianhuan Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash And Cash Equivalents
Get a 7-Day Free Trial Premium Member Only Premium Member Only 288.47 241.83 330.69 330.65 281.38

Jiangsu Lianhuan Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash And Cash Equivalents Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 253.87 210.64 204.43 281.38 237.13

Jiangsu Lianhuan Pharmaceutical Co Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.


Jiangsu Lianhuan Pharmaceutical Co  (SHSE:600513) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.


Jiangsu Lianhuan Pharmaceutical Co Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Jiangsu Lianhuan Pharmaceutical Co's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.


Jiangsu Lianhuan Pharmaceutical Co (SHSE:600513) Business Description

Traded in Other Exchanges
N/A
Address
No. 21 Wenfeng Road, Jiangsu Province, Yangzhou, Jiangsu, CHN, 225009
Jiangsu Lianhuan Pharmaceutical Co Ltd is engaged in producing benign prostatic hyperplasia, allergy and cardiovascular drugs.
Executives
Chu Qing Song senior management
Xia Chun Lai Director
Pan He Ping Directors, senior managers
Niu Ben senior management
Wu Wen Ge Director
Zhu Yong Jun senior management
Qian Zhen Hua Director
Shen Yi senior management
Huang Wen Tao senior management
Zhou Jun senior management
Tu Bin senior management
Qin Xiong Jian senior management

Jiangsu Lianhuan Pharmaceutical Co (SHSE:600513) Headlines

No Headlines